MONOCID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONOCID (MONOCID).
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites). |
| Half-life | Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min). |
| Protein binding | ~90% bound to serum albumin. |
| Volume of Distribution | 0.11-0.14 L/kg (low Vd indicates primarily confined to extracellular fluid; distributes into bile, sputum, pleural and synovial fluids; minimal CNS penetration unless inflamed meninges). |
| Bioavailability | Intramuscular: ~98% (nearly complete); Oral: not available (parenteral only). |
| Onset of Action | Intramuscular: 1-2 hours; Intravenous: immediate (peak levels achieved within 5-15 minutes post-IV infusion). |
| Duration of Action | Approximately 12-24 hours for susceptible organisms (due to long half-life, once-daily dosing is effective; duration may be shorter for more resistant pathogens or in neutropenic patients). |
| Molecular Weight | 473.54 |
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | Creatinine clearance (CrCl) 20-79 mL/min: 500 mg every 24 hours; CrCl <20 mL/min: 500 mg every 48 hours. Hemodialysis: 500 mg after each dialysis session. |
| Liver impairment | No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction. |
| Pediatric use | Children >6 months: 20-50 mg/kg intramuscularly or intravenously once daily; maximum 1 g/day. |
| Geriatric use | No specific dose adjustment based on age alone; adjust based on renal function per renal adjustment guidelines. |
| 1st trimester | Animal studies have shown fetal harm, but no adequate human studies. Use only if potential benefit justifies risk. |
| 2nd trimester | Avoid unless clearly needed; may cause fetal neutropenia and other adverse effects. |
| 3rd trimester | Avoid near term; risk of kernicterus in neonates due to bilirubin displacement. |
Clinical note
Comprehensive clinical and safety monograph for MONOCID (MONOCID).
| Placental transfer | Crosses placenta; achieves therapeutic concentrations in fetal serum. |
| Breastfeeding | Monocid is excreted in breast milk in low concentrations. Use with caution in nursing mothers due to potential for alteration of infant gut flora and allergic sensitization. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to cefonicid or any cephalosporinHistory of immediate-type hypersensitivity reaction to penicillins
| Precautions | Hypersensitivity reactions including anaphylaxis, Pseudomembranous colitis due to Clostridium difficile, Superinfection with prolonged use, Dosage adjustment in renal impairment (creatinine clearance < 20 mL/min), Use with caution in patients with history of penicillin allergy |
| Food/Dietary | No significant food interactions. Avoid alcohol during therapy and for 3 days after discontinuation due to risk of disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia). |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate human studies in pregnant women are lacking. No teratogenic effects reported in first trimester; use only if clearly needed during second and third trimesters. Potential for neonatal kernicterus if given near term due to bilirubin displacement. |
| Fetal Monitoring | Monitor maternal renal function (creatinine clearance) due to renal excretion; adjust dose if impaired. Observe for signs of superinfection or allergic reactions. Fetal monitoring not specifically required but standard prenatal surveillance recommended. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies showed no impairment of fertility at therapeutic doses. |
| Clinical Pearls |
| MONOCID (cefonicid) is a second-generation cephalosporin with a long half-life allowing once-daily dosing. It has poor CSF penetration; not for meningitis. Check for cross-allergy in penicillin-allergic patients (approx. 10%). Administer IM deep into large muscle to avoid pain and sterile abscess. Dose adjustment required in renal impairment (CrCl <50 mL/min). |
| Patient Advice | Take or receive this medication exactly as prescribed, usually once a day. · Complete the full course of treatment even if you feel better. · Report any signs of allergic reaction (rash, hives, difficulty breathing, swelling) immediately. · Inform your doctor if you have a history of penicillin or cephalosporin allergy. · Mild diarrhea is common; contact your doctor if diarrhea becomes severe or bloody. · Do not consume alcohol during treatment and for 72 hours after last dose to avoid disulfiram-like reaction. |